Adagene
MacroGenics Stops Bispecific Development; Third Arc Bio Signs $840M Licensing Deal with Adagene
MacroGenics; lorigerlimab; bispecific antibody; mCRPC; clinical trial halt; Third Arc Bio; Adagene; SAFEbody technology; CD3 T cell engagers; licensing agreement; biotech deals